Shuttle Pharmaceuticals Faces Nasdaq Listing Rule Violation
Ticker: SHPH · Form: 8-K · Filed: Sep 13, 2024 · CIK: 1757499
| Field | Detail |
|---|---|
| Company | Shuttle Pharmaceuticals Holdings, Inc. (SHPH) |
| Form Type | 8-K |
| Filed Date | Sep 13, 2024 |
| Risk Level | high |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.00001, $2,500,000, $801,434 |
| Sentiment | bearish |
Sentiment: bearish
Topics: listing-standards, delisting-risk, nasdaq
Related Tickers: RPHM
TL;DR
Nasdaq says Shuttle Pharma might get kicked off the exchange. They're figuring out what to do.
AI Summary
Shuttle Pharmaceuticals Holdings, Inc. received a notice on September 10, 2024, indicating it failed to meet a continued listing rule or standard for The Nasdaq Capital Market. The company is currently evaluating the notice and its options, which may include appealing the determination.
Why It Matters
Failure to meet listing standards could lead to delisting from Nasdaq, significantly impacting the company's stock liquidity and investor confidence.
Risk Assessment
Risk Level: high — The company has received a notice of non-compliance with Nasdaq listing rules, which could lead to delisting.
Key Players & Entities
- Shuttle Pharmaceuticals Holdings, Inc. (company) — Registrant
- Nasdaq Capital Market (company) — Exchange where listing standards are being evaluated
- September 10, 2024 (date) — Date of the notice
FAQ
What specific Nasdaq listing rule did Shuttle Pharmaceuticals Holdings, Inc. fail to meet?
The filing states that the company received a notice regarding failure to satisfy a continued listing rule or standard for The Nasdaq Capital Market, but does not specify which particular rule was violated.
What are the potential consequences of failing to meet Nasdaq's listing standards?
The primary consequence is the potential delisting of the company's securities from The Nasdaq Capital Market.
What actions is Shuttle Pharmaceuticals Holdings, Inc. taking in response to the notice?
The company is currently evaluating the notice and its options, which may include appealing the determination made by Nasdaq.
When did Shuttle Pharmaceuticals Holdings, Inc. receive this notice?
The company received the notice on September 10, 2024.
Does the filing indicate if the company has already been delisted?
No, the filing indicates the company received a notice of potential non-compliance and is evaluating its options, implying it has not yet been delisted.
Filing Stats: 698 words · 3 min read · ~2 pages · Grade level 13.6 · Accepted 2024-09-13 17:00:21
Key Financial Figures
- $0.00001 — ange on which registered Common Stock $0.00001 per share SHPH The Nasdaq Stock Mar
- $2,500,000 — intain stockholders' equity of at least $2,500,000. In the Company's Quarterly Report on F
- $801,434 — ompany reported stockholders' equity of $801,434, which is below the minimum stockholder
Filing Documents
- form8-k.htm (8-K) — 37KB
- 0001493152-24-036223.txt ( ) — 208KB
- shph-20240910.xsd (EX-101.SCH) — 3KB
- shph-20240910_lab.xml (EX-101.LAB) — 33KB
- shph-20240910_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Dated: September 13, 2024 By: /s/ Anatoly Dritschilo Name: Anatoly Dritschilo Title: Chief Executive Officer